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We have read with interest the paper by Liu and colleagues [1]. A very low incidence 
of ischaemic stroke (0.36%;7 patients) was reported in 1,946 consecutive procedures 
of catheter ablation of atrial fibrillation(AF). Findings are of importance but we 
would like to comment on two aspects that deserve reflection: 
Firstly, the authors have failed both to provide the prevalence of the different used 
anticoagulation regimens, and to assess their impact on cerebrovascular events 
(anticoagulation regimen was not included on logistic regression), which we believe 
should have been addressed in this study, as interruption of oral anticoagulation has 
previously been shown to be a major predictor of embolic events[2]. 
Second, the authors suggest that previous ischaemic stroke, mechanical valve 
replacement and CHA2DS2-VASc score ≥3 are independent predictors of 
cerebrovascular complications during catheter ablation of AF. We believe that such a 
definite conclusion, which intuitively makes sense, may be premature, at least for 
the following reasons: a) even though the authors present data from almost two 
thousand procedures, due to the extremely low event rate, we fear the study may 
be underpowered; b) most centres are currently performing AF ablation using 
uninterrupted anticoagulation[3], contrary to what we observe in this sample. 
Uninterrupted anticoagulation has shown to be associated with a lower rate of 
bleeding and embolic peri-procedural complications[2], and therefore we do not 
know if these single-centre data can be extrapolated to a wider population; c) in our 
single-centre experience of anticoagulation with heparin bridging (protocol and 
timing of anticoagulation interruption has been previously described[4]), in 1,483 
consecutive procedures from September 2010 to August 2013 we have also 
observed a low incidence of ischaemic stroke (0.40%;n=6). Assessment for predictors 
of ischaemic events in our sample does not reproduce the data from Liu and 
colleagues, as high CHA2DS2-VASc (one patient had a score of 3 and the remaining 
had 1 or 2), previous stroke (not present in any of our patients) and mechanical valve 
replacement (one patient had a previous mitral valve repair procedure) were not 
predictors of ischaemic cerebral events. On the other hand, CHADS2 and female 
gender were shown to be independent predictors in a previous randomized 
controlled trial including 1,584 patients[2]. Therefore, it is our belief that only a 
strong collaboration between high volume centres, with pooling of data from at least 
10,000 procedures may be necessary to provide a more solid answer to the unsolved 
issue of peri-procedural stroke during AF ablation.  
Previous evidence has suggested that these events may also occur more as a result 
of technical issues[5]. Procedural aspects (air embolism, intravenous heparin being 
given too late, sub-optimal ACT control, long radiofrequency application or warming 
up of the catheter tip with clot formation) may also be involved. However, as the 
latter may sometimes be unaccounted or under-reported in large registries, the 
occurrence of ischaemic events during catheter ablation of AF and the discovery of 
the true culprits may be a hard goal to achieve in the next years. 
In the mean time, according to the last Expert Consensus, a carefully planned and 
highly meticulous ablation procedure, in highly experienced centres using non-
interrupted anticoagulation and pre-procedural imaging may be the best way of 
minimizing the risk. 
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